

## AMENDMENT

Please amend the claims as follows:

Cancel claim 1.

G<sup>1</sup>  
2. (Amended) The [compound] peptide of claim [1] 27 wherein aa<sup>80</sup> is I.

3. (Amended) The [compound] peptide of claim [1] 27 wherein at least one of the amino acids is the D-isomer.

4. (Amended) The [compound] peptide of claim 3 wherein all of the amino acids are the D-isomer.

[Cancel claims 5-8.]

G<sup>2</sup>  
12. (Amended) The [compound] peptide of claim [1] 27 wherein aa<sup>82</sup> is L.

13. (Amended) The [compound] peptide of claim [1] 27 wherein aa<sup>83</sup> is R.

G<sup>3</sup>  
15. (Amended) The [compound] peptide of claim [1] 27 wherein [each of  $\alpha$  and  $\beta$  independently] comprises RIALRYYYRLAIR, YRLAIRRIALRY, RIALRYRILLRY or YRLIRYRLAIR.

16. (Amended) The [compound] peptide of claim [1] 27 which is YRLAIRLNERRENRLIALRY or YRLAIRLNERYRLAIRLNER.

17. (Amended) The [compound] peptide of claim [1] 27 which is YRLAIRRIALRY.

18. (Amended) A method for extending the period of acceptance by a recipient of a transplant from an allogenic or xenogenic MHC donor, said method comprising:

administering to said donor in accordance with a therapeutically effective regimen and in an amount effective to extend the period of acceptance of said transplant, the [compound] peptide of claim [1] 27; whereby the period of acceptance of said transplant is extended.

19. (Amended) The method of claim 18, wherein said compound is administered in combination with a subtherapeutic dosage of an immunosuppressant, and said period of acceptance is extended as compared to the period which would have resulted from the administering of said immunosuppressant as said subtherapeutic dosage in the absence of said peptide [compound].

20. (Amended) A composition comprising the [compound] peptide of claim [1] 27 and a subtherapeutic dosage of an immunosuppressant, together in an amount sufficient to inhibit transplant rejection in a mammal, in a physiologically acceptable medium.

21. (Amended) The peptide-type compound of claim [1] 27 which is a peptide and wherein all the amino acid residues in said peptide are gene-encoded.

Cancel nonelected claims 22-26. These claims may be pursued in a divisional application, if desired.

Kindly add the following claim (rewritten claim 1):

27 (Version A). A peptide dimer that inhibits cytotoxicity and consists of 12 to 60 amino acids, and has the one of the following structures:

R E aa<sup>77</sup> L R aa<sup>80-83</sup> Y (I) or

Y aa<sup>83-80</sup> R ~~E~~ aa<sup>77</sup> E R (II), and

N-terminal acylated and/or C-terminal amidated or esterified forms;

wherein:

aa<sup>77</sup> is D, S or N;

aa<sup>80</sup> is I or N;

aa<sup>81</sup> is A or L;

aa<sup>82</sup> is R or L;